MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Rhea-AI Summary

MEI Pharma (Nasdaq: MEIP) reported its financial results for the quarter ending September 30, 2024. The company is actively exploring strategic alternatives to maximize shareholder value, including out-licensing and M&A opportunities, with Oppenheimer & Co. as its exclusive financial advisor. MEI Pharma began cash preservation efforts in the first quarter of fiscal year 2025, including a reduction-in-force. The company holds $26.9 million in cash, cash equivalents, and short-term investments with no outstanding debt. There is no assurance that the exploration of strategic alternatives will result in any agreements or transactions, and the company does not expect to disclose further developments unless legally required or until the evaluation is complete.

Positive

• MEI Pharma holds $26.9 million in cash, cash equivalents, and short-term investments.
• No outstanding debt reported as of September 30, 2024.

Negative

• Commenced reduction-in-force as part of cash preservation efforts.
• Uncertainty around the success or attractiveness of potential strategic alternatives.

Reaffirms Continuation of Evaluation of Strategic Alternatives

SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended September 30, 2024.

As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process.

During the first quarter of fiscal year 2025, the Company commenced cash preservation efforts that include a reduction-in-force, which will continue in stages as the Company’s operational and strategic direction evolves.

There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.

As of September 30, 2024, MEI had $26.9 million in cash, cash equivalents, and short-term investments with no outstanding debt.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated cancer therapies. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.

Forward-Looking Statements

Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation and the increase in interest rates as a result; potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

MEI PHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value amounts)
	September 30,				June 30,
	2024				2024
	(Unaudited)				(Audited)
ASSETS
Current assets:
Cash and cash equivalents	$	6,952			$	3,705
Short-term investments		19,953				34,640
Prepaid expenses and other current assets		840				2,424
Total current assets		27,745				40,769
Operating lease right-of-use asset		—				214
Property and equipment, net		5				392
Total assets	$	27,750			$	41,375
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	976			$	3,168
Accrued liabilities		1,896				5,187
Total current liabilities		2,872				8,355
Total liabilities		2,872				8,355
Stockholders' equity:
Preferred stock, $0.01 par value; 100 shares authorized;
none outstanding		—				—
Common stock, $0.00000002 par value; 226,000 shares
authorized; 6,663 shares issued and outstanding
at September 30, 2024 and June 30, 2024, respectively		—				—
Additional paid-in-capital		421,104				421,239
Accumulated deficit		(396,226	)			(388,219	)
Total stockholders' equity		24,878				33,020
Total liabilities and stockholders' equity	$	27,750			$	41,375

MEI PHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
	For the Three Months Ended September 30,
	2024				2023
	(Unaudited)
Revenues	$	—			$	65,297
Operating expenses:
Research and development		3,163				3,485
General and administrative		5,189				6,531
Total operating expenses		8,352				10,016
(Loss) income from operations		(8,352	)			55,281
Other income (expense):
Interest and dividend income		355				1,094
Other expense, net		(10	)			(1	)
Net (loss) income	$	(8,007	)		$	56,374
Net (loss) income per share - basic and diluted	$	(1.20	)		$	8.46
Weighted-average shares used in computing net (loss) income per share - basic and diluted		6,663				6,663

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20241112133837/en/

Justin J. File

858-898-0976

investor@meipharma.com

Source: MEI Pharma, Inc.

FAQ

What is MEI Pharma's cash position as of September 30, 2024?

MEI Pharma reported having $26.9 million in cash, cash equivalents, and short-term investments as of September 30, 2024.

Is MEI Pharma exploring strategic alternatives?

Yes, MEI Pharma is continuing its review and evaluation of potential strategic alternatives, including out-licensing and M&A opportunities.

Who is advising MEI Pharma on their strategic alternatives?

Oppenheimer & Co. is serving as MEI Pharma's exclusive financial advisor in the evaluation of strategic alternatives.

What measures has MEI Pharma taken for cash preservation?

MEI Pharma has commenced cash preservation efforts that include a reduction-in-force.

Does MEI Pharma have any outstanding debt?

No, MEI Pharma reported having no outstanding debt as of September 30, 2024.